Prostate & Urologic Cancer Treatment

Prostate & Urologic Cancer Program

Overview

Specialists in the Prostate & Urologic Cancer at GSRO are renowned for their expertise in using advanced radiation therapies to treat cancers of the urinary tract (males and females) and the reproductive tract (males).

Each year we manage radiation therapy for many patients with genitourinary (GU) cancers of the prostate, bladder, kidneys, testes, penis, ureters, and urethra.

Personalized & Comprehensive Care

In the highly specialized Prostate & Urologic Cancer at Garden State Radiation Oncology, our radiation oncologist works side-by-side with your entire cancer treatment team. These world-class cancer specialists may include health care providers, including medical oncologists and surgeons, to meet the needs of each and every one of our patients.

Improving Patient Outcomes

To provide the best treatments for our patients, we understand it’s not just about the radiation machines. It's about advanced radiation technologies, plus the people who bring them to our patients.

The Prostate & Urologic Cancer Program uses the latest state-of-the-art and innovative technologies including:

  • Intensity-modulated radiation therapy (IMRT): Highly targeted conformal techniques are employed for all patients regardless of their disease or its location.
  • Image-guided radiation therapy (IGRT): Daily cone beam computed tomography (CBCT) is the cornerstone of our image-guidance practice. The majority of patients have fiducial markers inserted that aid in daily alignment, matching the daily CBCT with the planning CT.
  • Stereotactic body radiation therapy (SBRT) and Hypofractionation: These approaches are used to deliver a greater dose of radiation over a course of fewer treatments. GSRO now offers prostate treatment delivered in 4-5 weeks as compared to the 8-9 weeks given for traditional prostate radiotherapy. Five-fraction treatment, over just one week, has also been explored. Short courses of high dose radiation may now be safely given to sites of metastatic disease (when appropriate).